Depression, a common disease among the adult population, is also accepted as a risk factor for cardiovascular diseases.[@ref1]--[@ref5] Clinically apparent cardiovascular disease risk factors are hypertension, hyperlipidemia, hyperglycemia. However, the effects of selective serotonin reuptake inhibitors (SSRI), novel antidepressant drugs, on these risk factors remain unclear.

Fluoxetine has been reported to decrease blood glucose levels in obese non-insulin-dependent diabetics.[@ref6] An 8-week course of treatment with fluoxetine was also shown to decrease fasting blood glucose levels in major depressive disorder patients.[@ref7] Long-term use of antidepressant drugs (paroxetine, citalopram) decreased insulin requirement and glycosylated hemoglobin (HBA1C) levels in diabetic patients.[@ref8] In case of blood lipid levels, while paroxetine did not alter the levels of cholesterol, sertraline, fluoxetine and fluvoxamine increased cholesterol levels in a clinical study.[@ref9] In an another study, paroxetine and sertraline increased low density lipoprotein cholesterol (LDL-C) levels in depressive patients.[@ref10] In one case with social phobia severe hypertriglyceridemia was observed as a result of vDinleyinFonetik olarak okuyunenlafaxine and fluoxetine.[@ref11] While paroxetine increased total cholesterol, high density lipoprotein cholesterol (HDL-C) and LDL-C levels in patients with panic disorder, sertraline increased total cholesterol and LDL-C but did not affect HDL-C, and citalopram increased only HDL-C.[@ref12]

On the basis of these clinically confusing results, we aimed to investigate possible effects of sertraline, a widely used SSRI drug in the treatment of depression, on blood glucose and lipid levels which are risk factors for cardiovascular disease in depressive patients.

Methods {#sec1-1}
=======

This was a prospective clinical trial conducted on patients applied to the Psychiatry Clinic of Farabi Hospital in School of Medicine, Karadeniz Technical University. Patients (8 male and 12 female) diagnosed as depressive according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria who aged between 19-50 years, did not smoke, and had normal body mass index (BMI), homeostasis model assessment-estimated insulin resistance (HOMA-IR) values, blood pressure, blood glucose, insulin and lipid levels were included in our study. Afterwards, sertraline therapy (50 mg/day) was started ([Table 1](#T1){ref-type="table"}). At the beginning of the study, informed consents were taken from the patients. The study was approved by the Local Ethics Committee of School of Medicine, Karadeniz Technical University (approval number: 2007/10). Patients with diabetes mellitus, heart disease, pregnancy, or those taking other drugs were excluded from the study.

###### 

Demographic, physical and laboratory examination findings of patients
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 {#sec2-1}

### Study protocol: {#sec3-1}

Blood glucose, insulin, HDL-C, LDL-C, and triglyceride values were measured in patients before treatment with sertraline, and at the 4^th^, 8^th^ and 12^th^ weeks. HbA1C levels were measured at the beginning and at the end of the treatment (the 12^th^ weeks). All blood samples were taken at the same time of the day. Drug dose for each patient was determined by the psychiatrist. The study terminated at the end of the 12^th^ week and patients were treated by a psychiatrist afterwards.

Reference ranges of the measured parameters were as follows: glucose (60-110 mg/dl), insulin (2.6-25 μU/ml), HDL-C (30-70 mg/dl), LDL-C (60-130 mg/dl), HBA1C (4.2-6.4%), and triglyceride (50-175 mg/dl). Insulin levels were measured by electrochemiluminescence immunoassay method using Elecsys 2010 autoanalyzer. Glucose, HDL-C, LDL-C, triglyceride, and HbA1C were measured by a Roche-/Hitachi 912/917 autoanalyzer

### Statistical analyses: {#sec3-2}

The data is expressed as mean ± SD. Statistical analyses were performed using SPSS~17~. Due to violations of parametric test assumptions (non-normal distribution and low number cases), comparison of changes in measured values over time was carried out using Freidman test. Wilcoxon Signed Ranks test was then performed to show the significance of pairwise differences. The level of significance was set at p \< 0.05.

Results {#sec1-2}
=======

There were no significant differences in physical and laboratory examination findings between the 12^th^ week of treatment with sertraline and pretreatment values. The only significant difference was detected in insulin and triglyceride levels ([Table 2](#T2){ref-type="table"}). In addition, blood glucose values during treatment with sertraline did not significantly differ from pretreatment values ([Figure 1](#F1){ref-type="fig"}).

###### 

Pretreatment and post-treatment physical examination findings at the 12^th^ week of sertraline treatment
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![Pretreatment and post-treatment blood glucose levels at the 4^th^, 8^th^ and 12^th^ weeks of sertraline treatment\
\*: Compared with pretreatment values (p \< 0.05).](JRMS-16-1525-g003){#F1}

A significant increase was seen in blood insulin values obtained at the 4^th^, 8^th^ and 12^th^ weeks of treatment with sertraline compared to pretreatment values (p \< 0.05) ([Figure 2](#F2){ref-type="fig"}). There was no significant difference in HDL-C and LDL-C values during treatment with sertraline compared to pretreatment values ([Figure 3](#F3){ref-type="fig"}). However, triglyceride levels were significantly increased at the 8^th^ and 12^th^ weeks of treatment compared to pretreatment values (p \< 0.05) ([Figure 3](#F3){ref-type="fig"}). No significant difference was observed in HbA1C values compared to pretreatment value ([Figure 4](#F4){ref-type="fig"}).

![Pretreatment and post-treatment blood insulin levels at the 4^th^, 8^th^ and 12^th^ weeks of sertraline treatment\
\*: Compared with pretreatment values (p \< 0.05).](JRMS-16-1525-g004){#F2}

![Pretreatment and post-treatment blood HDL-C, LDL-C and triglyceride levels at the 4^th^, 8^th^ and 12^th^ weeks of sertraline treatment\
\*: Compared with pretreatment value (p \< 0.05).](JRMS-16-1525-g005){#F3}

![Pretreatment and post-treatment blood HbA1C levels at the 12^th^ week of sertraline treatment\
\*: Compared with pretreatment values (p \< 0.05).](JRMS-16-1525-g006){#F4}

Discussion {#sec1-3}
==========

There were not any differences in blood glucose and HbA1C levels between pre- and post-values in sertraline-treated patients with depressive disorder in our study. However, insulin levels were significantly increased at the 4^th^, 8^th^ and 12^th^ weeks compared with pretreatment values.

Erenmemisoglu et al. have shown that sertraline did not change insulin level but reduced blood glucose level in mice.[@ref13] Gomez et al. demonstrated that sertraline increased glucose-stimulated insulin secretion in rats.[@ref14][@ref15] However, clinical studies indicated sertraline to cause different incremental or decremental effects on blood glucose level.[@ref16][@ref17] A 180-day sertraline treatment reduced insulin requirement and HbA1C levels in diabetic patients.[@ref8] Sertraline, as a SSRI, may increase insulin secretion since serotonin increases insulin secretion in pancreas.[@ref18] In our study, while an increase in insulin levels was obtained, no change in blood glucose level was measured. Long-term use of SSRIs, e.g. fluoxetine and paroxetine, has been reported to decrease blood glucose levels in diabetic patients and major depressive disorder patients.[@ref6][@ref7] The difference between the results of these studies and our results might be explained by the difference in chemical structure, metabolism and pharmacokinetics of SSRI drugs which are a heterogeneous group of antidepressants. In addition, although we observed increased insulin levels, the levels were still in normal range and therefore did not affect blood glucose level. It should also be noted that the duration of this study could have been too short to show the chronic effects of sertraline on blood glucose level. Moreover, as hypothesized in literature,[@ref19] our results might also be explained by hepatic insulin-sensitizing substance (HISS). HISS is released from the liver by insulin. It acts selectively for skeletal muscles and leads to uptake and storage of glucose as glycogen in the large skeletal muscle masses. In the absence of HISS release, the response to insulin is reduced and more insulin has to be secreted from the pancreas.[@ref19][@ref20] Sertraline might prevent the release of HISS from the liver and may cause an increased insulin secretion to regulate glucose.

In the present study, although HDL-C and LDL-C levels in sertraline-treated patients with depressive disorder did not significantly differ from pretreatment values, triglyceride levels significantly increased at the 8^th^ and 12^th^ weeks. Several studies have reported the effects of sertraline on blood lipid levels in literature. Sertraline increased cholesterol levels in patients receiving psychiatric treatment.[@ref9]--[@ref12] Increased blood triglyceride levels during sertraline treatment in our study might have been due to increased insulin secretion and insulin\'s anabolic effects. Furthermore, HISS-dependent insulin resistance might also have been responsible. HISS causes the entrance of glucose into muscle cells resulting in triglyceride conversion to very low density lipoprotein (VLDL) by the liver. Blockade of HISS release prevents this usage of glucose in muscle cells. The excess amount of glucose enters adipose tissue and becomes a nutrient storage as lipids. However, during the blockage of HISS, the conversion of triglyceride to VLDL in the liver might be inhibited by sertraline.[@ref19]--[@ref21] So sertraline treatment may cause hypertriglyceridemia.

Unfortunately, there was a limitation in this study. The patients who were treated with sertraline and had no other health disorders were included in this study. Thus, the number of patients was limited.

Conclusion {#sec1-4}
==========

Based on our results and available literature, sertraline-treated patients have to be followed up for blood insulin and triglyceride levels. Their treatment plans need to be revised in order to adjust possible metabolic changes.
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